title: Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.
abstract: We investigated whole blood coagulation by thrombelastography (TEG) employing activation with minute amounts of tissue factor (TF). Continuous raw data captured were transformed into novel parameters, such as the maximum velocity (MaxVel) and the time to maximum velocity (t,MaxVel) of whole blood clot formation. The courses of the whole blood clot development were very similar to thrombin generation curves reported in plasma. In this assay healthy women (n = 30) showed an earlier onset and an increased coagulation velocity compared to healthy men (n = 30). In patients with severe hemophilia, and persons undergoing thromboprophylaxis, distinctly abnormal coagulation profiles were observed with a decrease in the MaxVel, as well as a prolonged t,MaxVel. Changes appeared to be dependent on the nature and severity of the hemostatic deficit. Preliminary studies in patients substituted with recombinant factor VIIa demonstrated a marked change in the coagulation profile, in which the MaxVel and t,MaxVel shifted towards normal in a dose-dependent way. Data suggest that the whole blood coagulation TEG profile, following activation with minute amounts of TF, may reflect the hemostatic potential in patients suspected of impaired hemostasis.
authors.affiliation: Center for Haemophilia and Thrombosis, Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Sørensen
authors.forename: P
authors.initials: P
authors.lastname: Johansen
authors.forename: K
authors.initials: K
authors.lastname: Christiansen
authors.forename: M
authors.initials: M
authors.lastname: Woelke
authors.forename: J
authors.initials: J
authors.lastname: Ingerslev
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D005167:Factor VII / Q000494:pharmacology / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D007700:Kinetics; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012737:Sex Factors; D013916:Thrombelastography; D013925:Thromboplastin / Q000494:pharmacology*; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005167:Factor VII; D013925:Thromboplastin; C103587:recombinant FVIIa; D015942:Factor VIIa